433 related articles for article (PubMed ID: 33481032)
1. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
[TBL] [Abstract][Full Text] [Related]
2. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
[TBL] [Abstract][Full Text] [Related]
3. Computational Phenomapping of Randomized Clinical Trials to Enable Assessment of their Real-world Representativeness and Personalized Inference.
Thangaraj PM; Oikonomou EK; Dhingra LS; Aminorroaya A; Jayaram R; Suchard MA; Khera R
medRxiv; 2024 May; ():. PubMed ID: 38798457
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
5. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM; Uyl-de Groot CA; van Moorselaar RJA; de Wit R; van den Bergh ACM; Coenen JLLM; Beerlage HP; Hendriks MP; Bos MMEM; van den Berg P; van de Wouw AJ; Spermon R; Boerma MO; Geenen MM; Tick LW; Polee MB; Bloemendal HJ; Cordia I; Peters FPJ; de Vos AI; van den Bosch J; van den Eertwegh AJM; Gerritsen WR
Eur Urol Focus; 2018 Sep; 4(5):694-701. PubMed ID: 28753794
[TBL] [Abstract][Full Text] [Related]
6. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
7. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With Lung Cancer.
Yuan Q; Cai T; Hong C; Du M; Johnson BE; Lanuti M; Cai T; Christiani DC
JAMA Netw Open; 2021 Jul; 4(7):e2114723. PubMed ID: 34232304
[TBL] [Abstract][Full Text] [Related]
8. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
9. Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis.
Koo KC; Lee JS; Kim JW; Han KS; Lee KS; Kim DK; Ha YS; Rha KH; Hong SJ; Chung BH
BMC Cancer; 2018 Apr; 18(1):468. PubMed ID: 29695228
[TBL] [Abstract][Full Text] [Related]
10. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets.
Murtojärvi M; Halkola AS; Airola A; Laajala TD; Mirtti T; Aittokallio T; Pahikkala T
Int J Med Inform; 2020 Jan; 133():104014. PubMed ID: 31783311
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
[TBL] [Abstract][Full Text] [Related]
14. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
Seyednasrollah F; Koestler DC; Wang T; Piccolo SR; Vega R; Greiner R; Fuchs C; Gofer E; Kumar L; Wolfinger RD; Kanigel Winner K; Bare C; Neto EC; Yu T; Shen L; Abdallah K; Norman T; Stolovitzky G; Soule HR; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Elo LL; Zhou FL; Guinney J; Costello JC;
JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657384
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Predict Postoperative Complications and Report on a Mobile Platform.
Ren Y; Loftus TJ; Datta S; Ruppert MM; Guan Z; Miao S; Shickel B; Feng Z; Giordano C; Upchurch GR; Rashidi P; Ozrazgat-Baslanti T; Bihorac A
JAMA Netw Open; 2022 May; 5(5):e2211973. PubMed ID: 35576007
[TBL] [Abstract][Full Text] [Related]
17. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
19. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
